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Abstract  
 
Rationale Self-titration is well documented in the tobacco literature. The extent to which e-
cigarette users (vapers) self-titrate is unknown.  
 
Objective This study explored the effects of high and low nicotine strength liquid on puffing 
topography, nicotine delivery and subjective effects in experienced vapers. 
 
Methods Eleven experienced male vapers completed 60 minutes of ad libitum vaping under 
low (6 mg/mL) and high (24 mg/mL) nicotine liquid conditions in two separate sessions. 
Measurements included: puffing topography (puff number, puff duration, volume of liquid 
consumed); and changes in: plasma nicotine levels, craving, withdrawal symptoms, self-
reported hit, satisfaction and adverse effects.  
 
Results Liquid consumption and puff number were higher, and puff duration longer, in the low 
nicotine strength condition (all ps < 0.01). The mean difference in nicotine boost from baseline 
in the low condition was 8.59 (7.52) ng/mL, 16.99 (11.72) ng/mL and 22.03 (16.19) ng/mL at 
10, 30 and 60 minutes respectively.  Corresponding values for the high condition were 33.77 
(34.88) ng/mL, 35.48 (28.31) ng/mL and 43.57 (34.78) ng/mL (ps < 0.05). There were no 
statistically significant differences between conditions in self-reported craving, withdrawal 
symptoms, satisfaction, hit or adverse effects.  
 
Conclusions Vapers engaged in compensatory puffing with lower nicotine strength liquid, 
doubling their consumption. Whilst compensatory puffing was sufficient to reduce craving and 
withdrawal discomfort, self-titration was incomplete with significantly higher plasma nicotine 
levels in the high condition.  
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Introduction 
 
Electronic cigarettes (e-cigarettes) are battery-operated devices which deliver nicotine via an aerosol 
typically containing nicotine (from 0 mg/mL concentration to 36 mg/mL), propylene glycol, 
vegetable glycerine and flavourings. E-cigarette use is on the increase: from 2.1 million users in 2014 
to 2.6 million in May 2015 in Great Britain, mostly comprising ex-smokers (ASH, 2015). Their 
increasing popularity and efficacy for quitting over conventional Nicotine Replacement Therapy 
(NRT) (Brown, Beard, Kotz, Michie & West, 2014) is commonly attributed to the ability to mimic 
the behavioural actions of cigarette smoking and to provide an analogous method of nicotine delivery 
(Polosa, et al., 2014). Although early studies in naive users reported poor nicotine delivery with little 
to no increase in blood nicotine levels (Bullen, McRobbie, Thornley, Glover, Lin & Laugesen), 2010; 
Eissenberg, 2010), later studies in experienced users and with newer models (Farsalinos, Spyrou, 
Tsimopoulou, Stefopoulos, Romagna & Voudris, 2014) have found pronounced increases paralleled 
by significant cigarette craving reduction (Etter, 2015). In fact, direct comparisons have demonstrated 
a 50% higher blood nicotine level in experienced versus naive e-cigarette users (Farsalinos et al., 
2015) and with a newer versus an older generation device (Farsalinos et al., 2014). 
 
Compared with smokers using tobacco cigarettes or e-cigarettes, experienced e-cigarette users 
(vapers) typically take longer puffs (Lee, Gawron & Goniewicz, 2015), although smokers may adjust 
their puffing patterns within a week of switching to e-cigarettes (Hua, Yip & Talbot, 2013; Lee, 
Gawron & Goniewicz, 2015; Talih et al., 2014). Machine-yield data consistently show that compared 
to tobacco cigarettes, e-cigarettes require a stronger suction to produce the aerosol (Trtchounian, 
Williams & Talbot, 2010). Thus longer e-cigarette puffs may be required to compensate for the less 
effective delivery method compared to tobacco smoking.  
 
Blood nicotine levels may also be influenced by puffing patterns (such as puff length, volume and 
frequency, known as puffing topography). We have previously observed large individual differences 
in plasma nicotine levels ranging from 13.4 ng/mL to 2.50 ng/mL after ten e-cigarette puffs, 
suggesting that users adjust their puff duration and/or volume to maintain a desired nicotine level (i.e. 
self-titrate) (Dawkins & Corcoran, 2014).  More recently, Ramôa and colleagues (Ramôa et al., 2015), 
using a ten-puff protocol reported that e-cigarette users increased their puff duration with 0 mg/mL 
compared with 36 mg/mL nicotine concentration (but not 8 or 18 vs. 36 mg/mL) which may reflect 
an attempt to self-titrate due to the absence of nicotine (Ramôa et al., 2015). Although this provides 
some evidence of titration, the use of a standardised ten min ten-puff protocol restricts users’ ability 
to compensate fully. Recent pilot work in our laboratory using an ad libitum design with low (6 
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mg/mL) and high (18 mg/mL) nicotine strength liquids also evidences compensatory puffing 
behaviour (greater liquid consumption and puff number, and longer puff duration in the low 
condition) and was the basis for this study.  Taken together these studies are suggestive of 
compensatory puffing behaviour in e-cigarette users.   
 
Compensatory smoking or nicotine titration is well documented in the tobacco smoking population; 
when given lower nicotine cigarettes, smokers increase their inhalation by taking more frequent and 
longer puffs or consuming more cigarettes (Ashton, 1979; Ashton & Watson, 1970; Russell, 1980; 
Russell, Jarvis, Iyer & Feyerabend, 1980; Russell, Wilson, Patel, Feyerabend & Cole, 1975; 
Woodward & Tunstall‐Pedoe, 1993). However, whilst self-report data (e.g. satisfaction) suggests that 
compensation could be effective (Sutton, Russell, Iyer, Feyerabend, & Saloojee, 1982), biomarkers 
suggest that compensation is seldom complete (Russell, Sutton, Iyer, Feyerabend, & Vesey, 1982). 
Conversely, there is no such direct empirical evidence from ad libitum protocols in e-cigarette users. 
Many e-cigarettes users gradually reduce their nicotine concentration over time (Polosa, Caponnetto, 
Cibella & Le-Houezec, 2015). Others may be obliged to do so with the implementation of the Tobacco 
Product Directive EU-TPD in Europe in May 2016, which will ban products exceeding 20 mg/mL 
nicotine concentrations (unless licensed as a medicine, for example, in the UK). Some, however, may 
need to increase their nicotine concentration in order to achieve complete smoking abstinence in the 
early stages of a cessation attempt (Farsalinos, Romagna, Tsiapras, Kyrzopoulos & Voudris, 2013). 
Documenting the behavioural and pharmacokinetic effects of switching to a lower nicotine strength 
liquid are therefore expedient in the current regulatory environment. 
 
We aimed to investigate to what extent, if at all, e-cigarette users self-titrate when given a lower 
nicotine strength liquid. We hypothesised that users will attempt to compensate by consuming more 
liquid and taking longer and more frequent puffs when using a lower nicotine strength liquid. 
Secondary aims were to explore subjective effects (craving, withdrawal symptoms, positive and 
negative reactions) and plasma nicotine concentrations between conditions (high vs. low nicotine 
concentration liquid).  
 
 
Methods 
 
Design and ethical approval 
The study received full ethical approval from the University of East London’s ethics committee 
(UREC_1415_40) and was conducted in accordance with the ethical standards outlined in the 1964 
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Declaration of Helsinki. All participants provided written informed consent to take part in the study 
and for the study to be written up for publication. 
 
A double-blind within-participants, counterbalanced design with 2 conditions: ‘low’ (6 mg/mL) and 
‘high’ (24 mg/mL) nicotine concentration liquid was used. Eleven (initially 12 but one was removed 
from all analyses due to inability to provide blood) regular e-cigarette users (all male ex-smokers), 
attended 2 separate sessions between 2 and 7 days apart at the University of East London. Participants 
responded to advertisements on social media sites, e-cigarette forums and emails. Eligibility criteria 
were: aged 18+; male (for ease of providing blood samples, see Dawkins & Corcoran, 2014); 
experienced e-cigarette user (daily use for > 3 months); currently using a second or third generation 
e-cigarette; familiar with 24 mg/mL nicotine concentration liquid (i.e. used 24mg/mL at least once in 
the last 6 months); baseline salivary cotinine levels > 100 ng/mL; CO levels ≤ 10 ppm; willing to 
provide saliva and blood samples and abstain from using nicotine for 12 h prior to study 
commencement.  
 
Randomisation and Masking 
Ten most popular brands of nicotine liquid were selected (search conducted in January/ February 
2015) and purchased online. One member of the research team selected a brand (Halo Smokers’ 
Angels) at random with nicotine concentrations of 6 and 24 mg/mL (50/50 ratio of propylene glycol 
to glycerine). Liquid was decanted into plain bottles and re-labelled X and Y, so brand and nicotine 
concentration were unknown to participants and participant-facing researchers. One researcher was 
responsible for filling the eVic™, another collected questionnaire data, and a phlebotomist collected 
blood; all were blind to nicotine condition. Order of presentation was counterbalanced and 
participants were randomly allocated to receive either X or Y first. 
 
Procedures 
Prior to testing, participants were sent an information sheet and screened via email and telephone. 
Pre-test saliva samples were collected by post and assessed for cotinine at Advanced Bioanalytical 
Service (ABS) Laboratories Ltd.  An ‘eVic™ supreme’ e-cigarette from Joyetech, fitted with a 
‘Nautilus Aspire’ tank was set at 3.9 V (8.5W) for an atomiser resistance of 1.8 ohm, and adjusted to 
the largest airflow. The tank was weighed at the beginning and end of each session to calculate the 
weight of liquid consumed.   This was then divided by the density of the liquid to calculate mL 
consumed for each participant in each of the two conditions.  
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Participants abstained from e-cigarette and nicotine use for 12 h prior to study commencement and 
were tested individually. Upon arrival, participants were offered a glass of water and provided written 
informed consent.  Smoking status was verified via carbon monoxide breath test and nicotine 
abstinence via baseline blood sample.  
 
Baseline and demographic characteristics including vaping history, e-cigarette dependence (measured 
via an adapted version of the Fagerström Test of Nicotine Dependence (Fagerström, 2012; eFTND, 
as described by Farsalinos et al., 2014), single-item rating of addiction from 0-100% (scored from 0 
= low addiction to 5 = very high addiction taken from the Cigarette Dependence Scale (CDS; Etter, 
Le Houezec & Perneger, 2003), current craving (‘urge to vape’) and withdrawal symptoms (Mood 
and Physical Symptoms Scale; MPSS) (West & Hajek, 2004) were collected before a phlebotomist 
inserted a venous cannula into the participant’s forearm and collected a baseline blood sample. 
Thereafter, the participant was presented with the eVic™ e-cigarette and asked to vape ad libitum for 
60 min. During this time participants read quietly, worked or engaged with social/other media using 
their own devices.  Further blood samples were taken, and craving and withdrawal symptoms 
recorded, at 10, 30 and 60 min after the first puff. Puffing topography (puff number and puff duration) 
was recorded by the eVic™ and downloaded to ‘My Vapors Joyetech 1.4’. Puff number and duration 
recorded using the eVic™ correlated highly with participant observation in our pilot study (r = .993, 
p < .001; r = .924, p = .025 for puff numbers and duration under low nicotine concentration 
respectively). The venous catheter was removed following the last blood sample collection at 60 min, 
before completion of a Visual Analogue Scale assessing positive (hit and satisfaction) and adverse 
effects associated with nicotine and e-cigarette use (Dawkins & Corcoran, 2014). Participant were 
then offered a snack and refreshment, thanked and reimbursed financially for their time (£50 
compensation) at the end of the second session.  
 
Blood collection and nicotine analysis 
Blood samples were collected using 4mL BD K2EDTA vacutainer tubes and stored in a polystyrene 
igloo away from the vaping area. Only the phlebotomist and a designated researcher (Hepatitis B 
vaccinated) handled blood samples. Prior to handling vacutainer tubes, hands were disinfected (with 
Virucidal alcohol hand gel) and gloves were worn and changed each time to avoid contamination. A 
different researcher handled the eVic™ and liquid to avoid blood sample contamination. After each 
testing session all blood samples were transported to an on-site forensic laboratory for plasma 
extraction. 
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Vacutainer tubes were placed in a ‘MSE Falcon 6/300R’ centrifuge system set to run as follows: 2000 
RCF, Temperature 4o C, for 10 min, to render samples acellular and obtain plasma. All samples were 
kept at -20 oC pending transportation to ABS Laboratories Ltd. for analysis using a validated LC-
MS/MS method with a lower limit of quantification (LOQ) of 0.5 ng/mL.  
 
Outcomes 
The primary outcome was puffing topography: i) mean number of puffs; ii) mean puff duration and, 
iii) volume of liquid consumed (in millilitres). Secondary outcomes were: change in plasma nicotine 
levels, change in craving and withdrawal symptoms and, self-reported hit, satisfaction and adverse 
effects. Change in plasma nicotine level (‘nicotine boost’) was calculated by subtracting baseline 
level from levels at 10, 30 and 60 min and reduction in craving and withdrawal symptoms by 
subtracting scores at 10, 30 and 60 from baseline scores. 
 
Statistical analysis 
Required sample size for detecting an effect on puffing topography was calculated using GPower 3.1 
using our pilot data. To detect a difference between conditions in mean number of puffs, puff duration 
and volume consumed at p < 0.05 with 95% CI, a sample of between N = 9 and 17 was required.  We 
planned to recruit 15 participants but due to participant drop out and failure to meet required baseline 
criteria, only 11 were tested. 
 
Data were analysed using ‘IBM SPSS Statistics 22’. Non-parametric statistics (Wilcoxon signed-rank 
tests for paired samples) were conducted to compare data between the high and low nicotine 
conditions as variable data were not normally distributed and transformations failed to correct to 
normal.  Spearman correlations were used to explore the relationship between plasma nicotine and 
puffing topography data. Accepted α level was 0.05 (all 2-tailed tests).  
 
 
 
Results 
 
Participant Characteristics 
Table 1 provides demographics baseline characteristics of the sample 
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Table 1 Participants' demographics and Baseline characteristics 
 N Percent. Mean SD Min Max 
Gender             
  Male 11 100         
  Female 0 0         
              
Age (years) 11   41.64 12.97 21 56 
              
Ethnicity             
  White 11 100         
              
Qualification             
 GSCEs level 4 36.4         
 A levels 2 18.2         
 Undergraduate level (5 to 6) 5 45.5         
              
Occupational status              
Employed 7 63.6         
Non-employed 2 18.2         
Self-employed 2 18.2         
               
eFTND1 11   4.73 1.35 2 7 
E-cig Addiction2 11  3.18 1.17 1 5 
       
Baseline cotinine levels (ng/mL) 11   466.63 250.25 134.2 890.6 
3-hydroxy-cotinine levels (ng/mL) 11  163.95 128.97 41.90 458.10
Cotinine to 3-hydroxy-cotinine ratio  11    .37 .27 .09   .86 
       
Baseline CO levels high strength 
(ppm) 11   2 1.26 1 4 
Baseline CO levels low strength (ppm) 11   2.18 1.33 1 5 
              
Nicotine strengths used (mg/mL)3             
  6 mg/mL 6 54.5         
  11mg/mL 3 27.3         
  18mg/mL 8 72.7         
  24 mg/mL 7 63.6         
  30 mg/mL 2 18.2         
Daily Liquid Vol consumed (mL) 11   4.09 1.79 2 7 
Current model most used             
  Rechargeable non-cigalike (2nd gen) 1 9.1         
  Modular systems (incl.sub-ohms4) 9 90.9         
1 eFTND = Fagerström Test of Nicotine Dependence for e-cigarettes with item regarding 
consumption removed (score range: 0-7) 
2 Self-rated addiction: 0-20% = 1; 21-40% = 2; 41-60% = 3; 61-80% = 4; 81-100% = 5 
3Note: participants could indicate multiple strengths, so does not add up to 11. 
4 i.e. atomiser resistance < 1ohm used with higher wattage 
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Puffing Topography 
We observed some instances of extremely short (i.e. <1s) puffs/button presses (9/568 puffs in the 
high condition and 15/887 puffs in the low condition; 1.58% and 1.69% respectively). These were 
verified against backup video data and deleted in cases where the device was not clearly in the mouth 
(N = 4). In all other instances the short puff preceded or succeeded a longer puff (by between 0.1 and 
1 s) and were therefore merged with the longer puff. 
 
There was a statistically significant difference between conditions in mean puff number, duration and 
volume of liquid (mL) consumed providing clear evidence for compensatory puffing (see Table 2).  
 
Table 2 Puffing topography (mean number of puffs and mean duration) 
 High Low 
 
Z p 
Puff number 48.36 (22.86) 70.73 (34.45) 
 
-2.40 0.016 
Puff duration (s) 3.84 (1.02) 5.20 (1.39) -2.93 0.003 
Liquid consumed 
(mL) 
0.64 (0.19) 1.23 (0.59) -2.93 0.003 
 
 
Blood Nicotine Delivery 
Figure 1 displays mean nicotine plasma levels over time for the low (6 mg/mL) and high (24 mg/mL) 
nicotine liquid conditions.  The mean (SD) difference in nicotine boost from baseline for the low 
nicotine condition was 8.59 (7.52) ng/mL, 16.99 (11.72) ng/mL and 22.03 (16.19) ng/mL at 10, 30 
and 60 minutes respectively.  Corresponding values for the high nicotine condition were 33.77 (34.88) 
ng/mL, 35.48 (28.31) ng/mL and 43.57 (34.78) ng/mL. These differences in plasma nicotine levels 
between conditions were statistically significant at each time point (10 min: Z = -2.85, p = 0.04; 30 
min: Z = -2.70, p = 0.007; 60 min: Z = -2.58, p=0.01).  
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Fig 1 Plasma nicotine concentration at baseline, 10, 30 and 60 min from the first puff, for the high 
and low nicotine conditions (N = 11; Error bars are ± 1 SEM)  
 
Correlations between puffing topography indices and plasma nicotine levels  
Puffing topography variables correlated positively with nicotine boost at each time point under both 
the high and low conditions (see Table 3). Effects were generally stronger in the high condition and 
for volume of liquid consumed and puff number; results did not reach statistical significance in the 
low condition for puff duration.  
 
Table 3  Correlations between plasma nicotine boost at each time point and puff number, puff 
duration and liquid consumption in the high and low nicotine conditions.   
High Nicotine Liquid Plasma Nicotine Boost 
 10 min 30 min 60 min 
 
Puff number .909** .875** .845** 
Puff Duration (s) .615** .588* .555* 
Liquid (mL) consumed   .845** 
 
 
   
Low Nicotine Liquid 
 
10 mins 30 mins 60 mins 
Puff number .403(ns) .714* .746** 
Puff duration (s) .544(ns) .189(ns) .216(ns) 
Liquid (mL) consumed 
 
  .745** 
*Correlation significant at 0.05 (2-tailed);  
**Correlation significant at 0.01 (2-tailed).  
NB: Puff number and duration at each time point are averages from baseline; Liquid (mL) consumed 
was only measured at 60 min. 
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Neither baseline cotinine, 3-hydroxy-cotinine or cotinine to 3-hydroxy cotinine ratio correlated with 
blood nicotine boost under high or low conditions at any time point (all rs < 0.44; all ps > 0.20) or 
with puffing topography variables (all rs < 0.05, all ps > 0.12), indicating that puffing topography 
was not affected by participants’ previous nicotine use or phenotypic status to metabolise nicotine. 
 
Subjective Effects 
As can be seen in Figures 2 and 3, self-reported urge to vape and nicotine-related withdrawal 
symptoms decreased over time in both the high and low nicotine liquid conditions. Change scores 
from baseline did not differ between conditions at any time point (all Z scores < 1, p > 0.3).   
 
 
  
Fig. 2 Urge to vape at baseline, 10, 30 and 60 min for the high and low nicotine conditions (N = 11; 
Error bars are ± 1 SEM) 
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Fig. 3 Withdrawal symptoms vape at baseline, 10, 30 and 60 min for the high and low nicotine 
conditions (N = 11; Error bars are ± 1 SEM) 
 
Mean (SD) percentage hit and satisfaction levels were 61.86 (31.50) and 60.70 (17.30) respectively 
in the high condition and 44.73 (23.00) and 46.89 (16.93) in the low condition. These differences did 
not reach statistical significance (hit: Z = -1.60, p= 0.11; satisfaction: Z = -1.69, p = 0.09). 
 
Adverse effect reporting was generally low (data not shown) with throat irritation, mouth irritation, 
sweaty and light-headedness being most commonly reported (all under 20%). One participant 
vomited 30 min into the first testing session (high nicotine condition). This participant had failed to 
consume breakfast and experienced anxiety over difficulty locating the study venue on a very hot 
day. Symptoms fully resolved within 20 min and the participant chose to continue with the study.  
 
Overall mean adverse effect percentage ratings were slightly higher (by 2%) in the high: 10.91 (8.60) 
versus low: 8.89 (5.65) nicotine condition (not statistically significant: Z = -1.17, P= 0.24). Analysis 
of individual symptoms revealed no significant differences across conditions (all ps > 0.09). 
 
 
DISCUSSION 
 
This study is the first to directly explore self-titration by allowing experienced e-cigarette users, 
habitually using high nicotine strength liquid, to vape ad libitum in the lab. The findings provide 
direct empirical evidence of a clear attempt to self-titrate; when given lower nicotine strength liquid, 
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users increased their puff frequency and duration and consumed more liquid.  As with tobacco 
smoking, compensation was partially effective; users reported equivalent reduction in urge to vape 
and withdrawal symptoms between conditions although blood nicotine levels were significantly 
higher in the high nicotine condition 
 
Consumption of liquid was doubled in the low versus high nicotine condition; mean puff number 
increased from 48.36 to 70.73 and puff duration from 3.84 to 5.20 s. These findings support the notion 
that users attempt to self-titrate by adjusting puffing behaviour to maximise nicotine delivery from a 
lower nicotine strength liquid. Indeed, indices of puffing patterns correlated positively with blood 
nicotine levels (with the exception of puff duration in the low nicotine condition). The phenomena of 
self-titration via compensatory puffing is well documented in the tobacco literature. Smokers increase 
puff frequency, duration and volume when switching to a lower nicotine cigarette whilst maintaining 
blood nicotine levels (Sutton et al., 1982). Similarly, here, although there was a 4-fold reduction in 
the nicotine strength of the low compared with the high liquid, corresponding plasma nicotine levels 
were only reduced by half at 30 and 60 min, but were at the expected level at 10 min (i.e. 
approximately 1/4 that of the high condition). Thus, compensatory puffing can be effective in raising 
blood nicotine levels but can take up to 30 min (at least with the concentrations used here) and, as 
with tobacco-smoking, does not appear to be complete (Ashton, Stepney & Thompson, 1979; Russell, 
Wilson, Patel, Feyerabend & Cole, 1975).  Incomplete self-titration may be due to a ‘saturation’ 
effect, that is, a limit on the volume of liquid that an individual can comfortably consume within a 
given time period, or because a given level of compensatory puffing is sufficient to achieve subjective 
satisfaction and alleviation of craving and withdrawal symptoms.   
 
Indeed, despite the difference in plasma nicotine concentrations, the magnitude of craving and 
withdrawal symptom reduction was similar across conditions suggesting effective compensatory 
puffing behaviour, at least in the short term. Hit and satisfaction were generally higher in the high 
nicotine condition but not significantly so.  There was however, considerable individual variation and 
the lack of a statistically significant effect may be related to the small sample size. Effects of puffing 
topography associated with different nicotine strength liquids on subjective effects certainly merit 
further exploration.  Adverse effects were uncommon and only 2% higher in the high nicotine 
condition.    
 
Although our participants demonstrate clear evidence of compensatory puffing, self-titration was far 
from perfect with significantly higher plasma nicotine levels in the high nicotine condition. We 
observed a mean plasma nicotine boost of 33.77 ng/mL in 10 min with some individuals achieving 
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considerably higher concentrations. This level exceeds those reported by other researchers using 
similar (Farsalinos et al., 2014; 2015) or higher nicotine e-liquid strength (Ramôa et al., 2015) and is 
equivalent to that observed in tobacco smokers (Russell, 1980, Russell et al., 1975) within 5 min of 
finishing a cigarette.  The high plasma nicotine levels are likely due to a combination of: the device 
used, our ad libitum vaping design, 12 h nicotine abstinence requirement and the nature of our 
participants.  The Aspire Nautilus tank used here is a more advanced system with more effective 
nicotine delivery to the aerosol (Farsalinos et al., 2016) compared to previous studies (Farsalinos et 
al., 2014; 2015; Ramôa  et al., 2015).  We also selected participants already familiar with using higher 
nicotine strength liquid and who had baseline salivary cotinine levels exceeding 100 ng/mL.  In fact, 
baseline salivary cotinine levels were very high (M: 467) similar to (indeed higher than) those 
typically seen in heavy smokers (334.83 ng/mL) (Russell, Jarvis, Devitt, Feyerabend, 1981). 
Although all participants were ex-smokers, a full smoking history and pre-quit salivary cotinine levels 
were not obtained so we cannot conclude whether nicotine exposure matched, exceeded or fell short 
of their pre-quit levels.  
 
Our study is one of the first (Farsalinos et al., 2015) to use inbuilt EC software to capture information 
on puffing topography, a straightforward and arguably more ecologically valid procedure than CReSS 
pocket devices. However, the eVic does not capture puff flow rate and, as a safety feature, stops 
functioning after a 10 s puff/button press. Nevertheless, recent findings suggest that puff velocity 
does not influence nicotine yield (Talih et al., 2014), >10 s puffs are rare (only 1.17% of all puffs in 
our study), and the CReSS device shares similar recording issues with a limit of 43 puffs. Despite 
methodological differences, puff durations under high and low nicotine conditions observed here are 
similar to those previously reported in experienced users using newer generation devices (Farsalinos 
et al., 2014; Hua et al., 2013) but longer than those reported for cartomiser (first-generation) devices 
(Behar, Hua, & Talbot, 2015) and tobacco cigarettes (Hua et al., 2013). Our study was conducted in 
a controlled laboratory environment which may not reflect real-world puffing behaviour (Robinson, 
Hensel, Morabito & Roundtree 2015) possibly over-estimating puffing. Indeed, the self-reported daily 
mL usually consumed (mean: 4.09 ± 1.79l; see Table 1) supports this notion, although the 12 h 
abstinence period may have also contributed to the intense puffing patterns as participants strive to 
raise fallen nicotine levels.  Similarly, the fixed device settings imposed here reflect standard second 
generation devices and allow a high degree of experimental control, but may not reflect how 
experienced third generation e-cigarette users behave.  
 
To conclude, vapers may opt for, or switch to, lower nicotine strength liquid for a variety of reasons: 
the belief that it is healthier; weaning off nicotine; or due to the implementation of the EU Tobacco 
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Products Directive (TPD). Our data suggest that experienced users tend to adjust their puffing patterns 
when switching to a lower nicotine liquid, maintaining adequate subjective effects, satisfaction and 
hit. It also suggests that very high nicotine levels are not absolutely necessary for alleviation of 
craving or withdrawal at least in acute conditions in the laboratory. Compensatory puffing patterns 
however, cannot fully compensate for the low nicotine delivery and increased puffing frequency 
results in increased costs and more frequent refills.  Those currently using nicotine levels exceeding 
20 mg/mL will be obliged to switch to lower nicotine strength liquids with the implementation of the 
TPD from May 2016.  Our results suggest that such individuals will increase their liquid consumption. 
If health risk is related to dose, and longer, more frequent puffing is associated with higher 
temperatures, this is likely to increase risk of exposure to potential toxins and carcinogens (Kośmider 
et al., 2014) although exposure is still likely to be considerably lower than from cigarette smoke. 
Electronic cigarettes have seen an unprecedented evolution in technology over the last five to six 
years. Here, using 24 mg/mL nicotine strength liquid, we observed high blood nicotine levels 
achieved very quickly, matching and even exceeding those reported in tobacco smokers. Although it 
may be at the detriment of continued nicotine dependence, such effective nicotine delivery may be 
important to increase the appeal of e-cigarettes and augment smoking cessation rates.   
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